172 related articles for article (PubMed ID: 24130878)
1. Direct interaction between AR and PAK6 in androgen-stimulated PAK6 activation.
Liu X; Busby J; John C; Wei J; Yuan X; Lu ML
PLoS One; 2013; 8(10):e77367. PubMed ID: 24130878
[TBL] [Abstract][Full Text] [Related]
2. p21-Activated kinase 6 (PAK6) inhibits prostate cancer growth via phosphorylation of androgen receptor and tumorigenic E3 ligase murine double minute-2 (Mdm2).
Liu T; Li Y; Gu H; Zhu G; Li J; Cao L; Li F
J Biol Chem; 2013 Feb; 288(5):3359-69. PubMed ID: 23132866
[TBL] [Abstract][Full Text] [Related]
3. Increased PAK6 expression in prostate cancer and identification of PAK6 associated proteins.
Kaur R; Yuan X; Lu ML; Balk SP
Prostate; 2008 Oct; 68(14):1510-6. PubMed ID: 18642328
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of p21-activated kinase 6-mediated inhibition of androgen receptor signaling.
Schrantz N; da Silva Correia J; Fowler B; Ge Q; Sun Z; Bokoch GM
J Biol Chem; 2004 Jan; 279(3):1922-31. PubMed ID: 14573606
[TBL] [Abstract][Full Text] [Related]
5. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
6. Regulator of G-protein signaling 2 (RGS2) inhibits androgen-independent activation of androgen receptor in prostate cancer cells.
Cao X; Qin J; Xie Y; Khan O; Dowd F; Scofield M; Lin MF; Tu Y
Oncogene; 2006 Jun; 25(26):3719-34. PubMed ID: 16449965
[TBL] [Abstract][Full Text] [Related]
7. AR and ER interaction with a p21-activated kinase (PAK6).
Lee SR; Ramos SM; Ko A; Masiello D; Swanson KD; Lu ML; Balk SP
Mol Endocrinol; 2002 Jan; 16(1):85-99. PubMed ID: 11773441
[TBL] [Abstract][Full Text] [Related]
8. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells.
Xie Y; Wolff DW; Lin MF; Tu Y
Mol Pharmacol; 2007 Jul; 72(1):73-85. PubMed ID: 17430995
[TBL] [Abstract][Full Text] [Related]
9. Enrichment of putative prostate cancer stem cells after androgen deprivation: upregulation of pluripotency transactivators concurs with resistance to androgen deprivation in LNCaP cell lines.
Seiler D; Zheng J; Liu G; Wang S; Yamashiro J; Reiter RE; Huang J; Zeng G
Prostate; 2013 Sep; 73(13):1378-90. PubMed ID: 23728788
[TBL] [Abstract][Full Text] [Related]
10. MUC1-C oncoprotein confers androgen-independent growth of human prostate cancer cells.
Rajabi H; Ahmad R; Jin C; Joshi MD; Guha M; Alam M; Kharbanda S; Kufe D
Prostate; 2012 Nov; 72(15):1659-68. PubMed ID: 22473899
[TBL] [Abstract][Full Text] [Related]
11. Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation.
Mahajan NP; Liu Y; Majumder S; Warren MR; Parker CE; Mohler JL; Earp HS; Whang YE
Proc Natl Acad Sci U S A; 2007 May; 104(20):8438-43. PubMed ID: 17494760
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor and chemokine receptors 4 and 7 form a signaling axis to regulate CXCL12-dependent cellular motility.
Hsiao JJ; Ng BH; Smits MM; Wang J; Jasavala RJ; Martinez HD; Lee J; Alston JJ; Misonou H; Trimmer JS; Wright ME
BMC Cancer; 2015 Mar; 15():204. PubMed ID: 25884570
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor specifically interacts with a novel p21-activated kinase, PAK6.
Yang F; Li X; Sharma M; Zarnegar M; Lim B; Sun Z
J Biol Chem; 2001 May; 276(18):15345-53. PubMed ID: 11278661
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells.
Hååg P; Bektic J; Bartsch G; Klocker H; Eder IE
J Steroid Biochem Mol Biol; 2005 Aug; 96(3-4):251-8. PubMed ID: 15982869
[TBL] [Abstract][Full Text] [Related]
15. Fulvestrant (ICI 182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells.
Bhattacharyya RS; Krishnan AV; Swami S; Feldman D
Mol Cancer Ther; 2006 Jun; 5(6):1539-49. PubMed ID: 16818513
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptor gamma coactivator-1alpha interacts with the androgen receptor (AR) and promotes prostate cancer cell growth by activating the AR.
Shiota M; Yokomizo A; Tada Y; Inokuchi J; Tatsugami K; Kuroiwa K; Uchiumi T; Fujimoto N; Seki N; Naito S
Mol Endocrinol; 2010 Jan; 24(1):114-27. PubMed ID: 19884383
[TBL] [Abstract][Full Text] [Related]
17. Cyclin G-associated kinase: a novel androgen receptor-interacting transcriptional coactivator that is overexpressed in hormone refractory prostate cancer.
Ray MR; Wafa LA; Cheng H; Snoek R; Fazli L; Gleave M; Rennie PS
Int J Cancer; 2006 Mar; 118(5):1108-19. PubMed ID: 16161052
[TBL] [Abstract][Full Text] [Related]
18. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
[TBL] [Abstract][Full Text] [Related]
19. Vav3, a Rho GTPase guanine nucleotide exchange factor, increases during progression to androgen independence in prostate cancer cells and potentiates androgen receptor transcriptional activity.
Lyons LS; Burnstein KL
Mol Endocrinol; 2006 May; 20(5):1061-72. PubMed ID: 16384856
[TBL] [Abstract][Full Text] [Related]
20. Difference in protein expression profile and chemotherapy drugs response of different progression stages of LNCaP sublines and other human prostate cancer cells.
Lin HP; Lin CY; Hsiao PH; Wang HD; Jiang SS; Hsu JM; Jim WT; Chen M; Kung HJ; Chuu CP
PLoS One; 2013; 8(12):e82625. PubMed ID: 24349321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
